1	TO THE HOUSE OF REPRESENTATIVES:
2	The Committee on Human Services to which was referred Senate Bill No.
3	14 entitled "An act relating to single dose, child-resistant packaging and
4	labeling of marijuana-infused edible or potable products sold by a registered
5	dispensary" respectfully reports that it has considered the same and
6	recommends that the House propose to the Senate that the bill be amended as
7	follows:
8	First: In Sec. 1, 18 V.S.A. § 4472, after "§ 4472. DEFINITIONS"
9	by adding the following:
10	As used in this subchapter:
11	(1)(A) "Bona fide health care professional-patient relationship" means a
12	treating or consulting relationship of not less than six three months' duration, in
13	the course of which a health care professional has completed a full assessment
14	of the registered patient's medical history and current medical condition,
15	including a personal physical examination.
16	(B) The six-month three-month requirement shall not apply if:
17	(i) a patient has been diagnosed with:
18	(A)(I) a terminal illness;
19	(B)(II) cancer with distant metastases; or
20	(C)(III) acquired immune deficiency syndrome.

1	(11) a patient was diagnosed with a debilitating medical condition
2	by a health care professional in another jurisdiction in which the patient was
3	formerly a resident and the patient, now a resident of Vermont, has the
4	diagnosis confirmed by a health care professional in this State or a neighboring
5	state as provided in subdivision (6) of this section, and the new health care
6	professional has completed a full assessment of the patient's medical history
7	and current medical condition, including a personal physical examination.
8	(iii) a patient who is already on the registry changes health care
9	professionals three months or less prior to annual renewal of the patient's
10	registration, provided the patient's new health care professional has completed
11	a full assessment of the patient's medical history and current medical condition
12	including a personal physical examination.
13	* * *
14	(4) "Debilitating medical condition," provided that, in the context of the
15	specific disease or condition described in subdivision (A) or (B) of this
16	subdivision (4), reasonable medical efforts have been made over a reasonable
17	amount of time without success to relieve the symptoms, means:
18	(A) cancer, multiple sclerosis, positive status for human
19	immunodeficiency virus, acquired immune deficiency syndrome, glaucoma, or
20	the treatment of these conditions, if the disease or the treatment results in
21	severe, persistent, and intractable symptoms; or

1	(B) a disease, medical condition, or its treatment that is chronic,
2	debilitating, and produces severe, persistent, and one or more of the following
3	intractable symptoms: cachexia or wasting syndrome; severe pain; severe
4	nausea; or seizures.
5	* * *
6	Second: In Sec. 1, 18 V.S.A. § 4472, by adding a new subdivision (14) to
7	read as follows:
8	(14) "Terminal illness" means an incurable and irreversible disease
9	which would, within reasonable medical judgment, result in death.
10	and by renumbering the remaining subdivisions to be numerically
11	correct.
12	Third: In Sec. 4, 18 V.S.A. § 4474e, by adding a subdivision (a)(4) to read
13	as follows:
14	(4) With approval from the Department and in accordance with patient
15	delivery protocols set forth in rule, transport and transfer marijuana to a
16	Vermont post-secondary academic institution for the purpose of research.
17	
18	
19	
20	(Committee vote:)

1	
2	Representative
3	FOR THE COMMITTEE

(Draft No. 3.1 – S.14)

4/28/2016 - MRC - 03:39 PM

Page 4 of 4